Late-breaking clinical trials presented at the 2005 and 2006 annual scientific meetings of
the ACC, AHA, and European Society of Cardiology, as well as selected other data, were …

… Krumholz … In addition, the virus can survive for 24 to 72 h on surfaces, depending on the
type of … Han H., Yang L., Liu R., et al. "Prominent changes in blood coagulation of patients with …

Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …

… • Bivalirudin: 0.75-mg/kg IV bolus, then 1.75–mg/kg/h infusion with or without … 48 h or until
revascularization. IV bolus of 60 U/kg (maximum 4000 U) followed by an infusion of 12 U/kg/h (…

… Once it has been established that no biomarker of myocardial necrosis has been released
(based on 2 or more samples collected at least 6 h apart, with a reference limit of the 99th …

The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular …

Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

… , reteplase, and tenecteplase) fibrinolytic-treated patients, a 60 U/kg bolus followed by a
maintenance infusion of 12 U/kg per hour (with a maximum of 4000 U bolus and 1000 U/h initial …

ContextDespite the importance of diversity of cancer trial participants with regard to race,
ethnicity, age, and sex, there is little recent information about the representation of these groups …

The process of guideline development for management of patients with acute myocardial
infarction (AMI) has undergone substantial evolution since the inaugural publication entitled “…